2
Clinical Trials associated with PA-001 (Peptidream) / Not yet recruitingPhase 1 A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS
The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults.
Participants will receive either:
* an experimental PG4 vaccine
* a PG4 vaccine comparator
* a standard 20vPnC vaccine comparator
* placebo. A placebo does not have any medicine in it but looks just like the study medicine.
Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to two doses of study vaccine or comparator and take part in follow-up visits.
At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during clinic visits.
/ CompletedNot ApplicableIIT First-in-Human Study for the Evaluation of the Safety of PA-001 in Japanese Healthy Male Subjects (COVID-19)
Start Date21 Feb 2022 |
Sponsor / Collaborator- |
100 Clinical Results associated with PA-001 (Peptidream)
100 Translational Medicine associated with PA-001 (Peptidream)
100 Patents (Medical) associated with PA-001 (Peptidream)
100 Deals associated with PA-001 (Peptidream)